EZH2 and B-cell non-Hodgkin lymphoma: Treatment with EZH2 inhibitors is being investigated in follicular and B-cell lymphomas with activating EZH2 mutations [156], and in solid tumors with overexpression of EZH2 [157,158], which are associated with a poorly differentiated phenotype [159].